An open-label, exploratory study of the pharmacokinetic and pharmacodynamic activity of MabThera (rituximab) in combination with methotrexate in synovial tissue and in peripheral blood of patients with active rheumatoid arthritis.
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2014
At a glance
- Drugs Rituximab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 15 Jul 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 17 Dec 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.